Chronic rhinosinusitis (CRS) is an inflammatory condition that leads to prolonged periods of nasal congestion, facial discomfort, pressure, and nasal discharge, often lasting for months or even years. In the United States, roughly 8 million people are treated for CRS annually. It can manifest as either chronic sinusitis without nasal polyps, chronic sinusitis with nasal polyps, or allergic fungal rhinosinusitis.
Dupixent, Xolair, Xhance and Nucala are some of the FDA-approved drugs for chronic sinusitis with nasal polyps. Xhance is also approved for the treatment of chronic rhinosinusitis without nasal polyps, and it is the first and only medication indicated for this condition.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.